Sandu Pharmaceuticals (524703) Q4 23/24 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the quarter and year ended March 31, 2024, were approved with an unmodified opinion from the statutory auditors.

• The company operates in a single segment: Ayurvedic Proprietary Medicine.

• A wholly-owned subsidiary, Sandu Phytocetucials Pvt Ltd, was formed but has not yet commenced production; related expenses are included in consolidated results.

Financial highlights

• Standalone revenue from operations for FY24 was ₹6,728.07 lakhs, up from ₹6,534.90 lakhs in FY23.

• Standalone net profit for FY24 was ₹146.07 lakhs, compared to ₹152.41 lakhs in FY23.

• Consolidated revenue from operations for FY24 was ₹6,728.07 lakhs, with consolidated net profit at ₹146.12 lakhs.

• Total comprehensive income (standalone) for FY24 was ₹207.56 lakhs, compared to ₹209.36 lakhs in FY23.

• Earnings per share (EPS) for FY24 stood at ₹1.51 (standalone) and ₹1.51 (consolidated).

Outlook and guidance

• The board and audit committee reviewed and approved the results, with no material uncertainties regarding going concern.